Bovie Medical Corporation Announces First Quarter Financial Results; Growthink Securities Inc. Named Strategic Advisor
Bovie Medical Corporation (the “Company”) (NYSE Amex: BVX), a manufacturer and marketer of electrosurgical products, today announced its financial results for the first quarter ended March 31, 2010.
Revenues for the quarter ended March 31, 2010 totaled $5,599,107 versus $7,217,324 for the comparable period last year; resulting in net loss of $(225,774) or $(0.01) per diluted share as compared to net income of $403,266 or $.02 per diluted share in the same period in the prior year. While OEM business declined and is difficult to predict, the Company anticipates an improvement in non-OEM and new product sales.
The Company also announced today that it has retained Growthink Securities, Inc. to assist Bovie as its strategic consulting, business planning and financial advisor in connection with developing various sales and marketing strategies, any potential financing and/or sale transaction, related to one or more of Bovie’s medical device product lines. Growthink services include strategic business planning consulting, investment banking, market research, feasibility studies and private equity investing.
NEW PRODUCT ACTIVITIESAndrew Makrides, president of Bovie, stated, “While management is disappointed in the first quarter’s results, we continue to work to improve the Company’s bottom line by cutting costs and increasing efficiencies. The Company remains optimistic regarding its future prospects and its new proprietary products targeted towards the higher margin hospital, surgi-centers and specialty markets. Recent progress with our Sintered Steel technology highlighted by FDA clearance of the soon to be launched BOSS™ device, adds to our optimism. Pre-clinical testing for the Seal-N-Cut™ vessel sealing instrument line has been scheduled to collect data for a 501k submission, while plans for marketing the product are moving forward. J-Plasma, a product with multi-market potential, is advancing toward market availability during 2010. We understand shareholder impatience and frustration with perceived delays in new product introductions into the marketplace. However, the lengthy process of developing new technologies into new products is often the result of regulatory hurdles that must be overcome. Additionally, our recent $3.0 million private placement will be directed at marketing our new products, while not precluding a large company collaboration.”
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV